SuperworthElevance Health ELV
- Market cap
- $95.4B
- PE
- 19.6×
- 10y median 17.6×
- Forward PE
- 16.1×
- 10y median 14.8×
- Price to sales
- 0.5×
- EV/EBIT
- 13.6×
- Revenue, 12 months
- $201.1B
- +6% on a year ago
- Net margin
- 2.5%
- Free cash flow yield
- 6.6%
Elevance Health trades at 19.6× trailing earnings, pricier than 79% of the last ten years. Revenue was $201.1B over the last twelve months, up 6% on a year earlier with a 2% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $42.8B+7% | $42.6B+7% | $42.6B+1% | $43.9B+1% | $45.1B+5% | $45.4B+7% | $48.9B+15% | $49.8B+13% | $50.7B+12% | $49.7B+10% | $50.2B+3% | $50.5B+1% | |
| Cost of revenue | $4.6B+35% | $4.8B+33% | $3.8B+10% | $4.8B+11% | $5.1B+10% | $6B+24% | $5B+30% | $5.3B+10% | $5.4B+6% | $5.5B−8% | $5.5B+10% | $5.5B+4% |
| Gross profit | $38.2B+5% | $37.8B+4% | $38.8B+0% | $39.1B−1% | $40B+5% | $39.4B+4% | $43.9B+13% | $44.5B+14% | $45.3B+13% | $44.2B+12% | $44.7B+2% | $45B+1% |
| SG&A | $5.5B+21% | $5B+10% | $4.9B+2% | $5.1B+5% | $5.3B−4% | $4.8B−4% | $5.3B+9% | $5B−1% | $5.3B+0% | $5.4B+13% | $6.3B+19% | $5.5B+11% |
| Interest expense | $259M+22% | $259M+13% | $265M+6% | $280M+7% | $300M+16% | $340M+31% | $344M+30% | $341M+22% | $351M+17% | $366M+8% | $357M+4% | $364M+7% |
| Pre-tax income | $1.7B−22% | $1B−4% | $2.9B+12% | $3B+22% | $1.4B−17% | $606M−40% | $2.8B−5% | $2.3B−23% | $1.4B+2% | $215M−65% | $2.3B−18% | $1.9B−16% |
| $354M−33% | $170M+1% | $690M+12% | $685M+17% | $365M+3% | $193M+14% | $613M−11% | $548M−20% | $219M−40% | −$331M | $544M−11% | $483M−12% | |
| Net income | $1.3B−20% | $856M−1% | $2.2B+13% | $2.3B+24% | $1B−21% | $418M−51% | $2.2B−3% | $1.7B−24% | $1.2B+17% | $547M+31% | $1.8B−19% | $1.5B−16% |
| $5.45−18% | $3.63+1% | $9.59+16% | $9.85+26% | $4.36−20% | $1.81−50% | $9.61+0% | $7.72−22% | $5.32+22% | $2.47+37% | $8.00−17% | $6.71−13% | |
| 236.5M−2% | 235.6M−2% | 234.2M−2% | 233.4M−2% | 233.1M−1% | 230.8M−2% | 227.2M−3% | 225.8M−3% | 223.7M−4% | 221.6M−4% | 220.4M−3% | 217.9M−4% |
Gross profit: 39 periods, Q3 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: Q4 FY08: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'. 6 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q2 FY08 to Q1 FY09: not printed by the filing, worked out from its own lines. 17 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $49.3B | $47.9B to $51.4B | $4.71 | $4.64 to $5.06 | 14 |
| Q4 FY26 | $49.3B | $47.4B to $51.9B | $2.10 | $1.91 to $2.55 | 13 |
| Q1 FY27 | $50.5B | $49.2B to $53.7B | $12.38 | $10.48 to $14.16 | 10 |
| Q2 FY27 | $51.2B | $49.6B to $53.3B | $8.17 | $7.85 to $8.60 | 8 |
| Q3 FY27 | $51.5B | $50B to $53.7B | $6.14 | $5.91 to $6.47 | 8 |
| Q4 FY27 | $50.5B | $49B to $52.6B | $3.66 | $3.52 to $3.86 | 8 |
| Q1 FY28 | $52.2B | $50.6B to $54.3B | $13.31 | $12.79 to $14.02 | 9 |
| Q2 FY28 | $52.9B | $51.4B to $55.1B | $8.92 | $8.58 to $9.40 | 9 |
Peers
Companies in Medical - Healthcare Plans nearest Elevance Health's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ELVElevance Health | $95.4B | 19.6× | 17.6× | 16.1× | 0.5× | +6% | 2.5% |
| CICigna | $81.1B | 12.7× | 16.1× | 9.7× | 0.3× | +8% | 2.3% |
| CVSCVS Health | $119.5B | 24.7× | 16.2× | 11.5× | 0.3× | +7% | 1.2% |
| HUMHumana | $50.7B | 39.9× | 20.7× | 33.7× | 0.3× | +18% | 0.9% |
| CNCCentene | $34.7B | n/m | 20.7× | 15.0× | 0.2× | +14% | −2.5% |
| UNHUnitedHealth | $375.3B | 23.9× | 22.7× | 18.5× | 0.8× | +3% | 3.5% |
| OSCROscar Health | $9.6B | 22.3× | 47.9× | n/m | 0.6× | +43% | 3.6% |
| Peer median | $65.9B | 23.9× | 20.7× | 15.0× | 0.3× | +11% | 1.7% |
Investors who own it
Investors we follow who held Elevance Health at the end of Jun 30, 2026, from their 13F filings.
- Seth KlarmanBaupost Group9.1% of portfolio
- Ruane, Cunniff & GoldfarbRuane, Cunniff & Goldfarb (Sequoia Fund)5.9% of portfoliotrimmed
- Bill NygrenHarris Associates (Oakmark)2.5% of portfolioadded
- Baillie GiffordBaillie Gifford0.4% of portfoliotrimmed
- Ron BaronBaron Capital0.0% of portfolionew
More on Elevance Health
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 11Health insurers with the highest profit margins
- #4of 10Health insurers with the lowest EV/EBIT
- #7of 11Health insurers with the lowest price to sales ratio
- #9of 11Health insurers with the fastest revenue growth
Its groups
About
- Industry
- Medical - Healthcare Plans
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .